Thomas KS, Batchelor JM, Akram P, et al. - In this pragmatic, 3‐arm, placebo‐controlled RCT (9 months’ treatment; 12 months’ follow‐up), researchers sought to determine the efficacy of hand‐held narrowband‐UVB (NB‐UVB) and combination of a potent topical corticosteroid (TCS) and NB‐UVB compared with TCS, for localised vitiligo. Adults and children, selected from secondary care and community, aged ≥ 5 years with active vitiligo affecting < 10% of skin, have been randomized 1:1:1 to obtain: TCS (mometasone furoate 0.1% ointment + dummy NB‐UVB); NB‐UVB (NB‐UVB + placebo TCS); or combination (TCS + NB‐UVB). Five hundred seventeen candidates were randomized: TCS (n =173), NB‐UVB (n = 169), combination (n = 175). Primary outcome data were available for 370 candidates. For the treatment of localised vitiligo, combination therapy with home‐based hand‐held NB‐UVB plus TCS is likely to be superior to TCS alone. The combination treatment was relatively safe and well-tolerated, but only successful in about a quarter of the participants.